Project Grant R37AI198014
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $776,872 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on serological correlates of survival in HIV-associated cryptococcal meningitis. The research investigates plasma immunoglobulin measures associated with survival and treatment response in people with HIV and cryptococcal meningitis, a devastating CNS infection caused by...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded Brandeis University $841,708 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on sulfur-substituted glycoconjugate immunogens designed to elicit broadly-neutralizing antibodies against HIV. The funded research investigates how high-mannose glycans stabilized against mannosidase...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $832,773 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance an "induce-and-clear" therapeutic strategy targeting HIV-1 latent cellular reservoirs. The research integrates RNA-based latency reversal with engineered high-avidity antibodies to overcome barriers to immune clearance of persistent HIV infection. The project...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, College Park $1,498,706 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the cellular and molecular mechanisms of cryptococcal immune reconstitution inflammatory syndrome (IRIS). The recipient will use a novel murine model of Cryptococcus neoformans infection to identify the leukocyte subsets and cytokines mediating lethal cryptococcal IRIS, and to...
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...
- The National Institute of Allergy and Infectious Diseases awarded East Carolina University $536,695 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 1, 2026. The award funds research into the roles of fibroblastic reticular cells (FRCs) in the establishment and maintenance of HIV-1 latently infected cells containing intact proviruses in people living with HIV under antiretroviral therapy. The project examines how FRCs, a type of secondary lymphoid organ stromal...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $1,267,667 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate prime-boost immunization regimens targeting broadly neutralizing antibodies in early-life HIV vaccination. The Project Grant (R01AI203537) funds research testing germline-targeting strategies that use minimal epitope immunogens delivered via clinically approved...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $3.204 million on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the interaction between TAR RNA and INI1/SMARCB1, a component of the BAF chromatin remodeling complex, and its role in HIV-1 transcriptional regulation and latency reactivation. The research examines how INI1's winged helix DNA-binding domain binds to TAR RNA to facilitate...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $780,787 on January 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on how T cell receptor recognition of peptide ligands shapes memory CD8+ T cell programming. The research will identify features of T cell epitopes, T cell receptor structural modes of recognition, T cell receptor signaling pathways, and genetic and epigenetic regulators...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...